2016
Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A
Hartley M, Bourreau E, Rossi M, Castiglioni P, Eren R, Prevel F, Couppié P, Hickerson S, Launois P, Beverley S, Ronet C, Fasel N. Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A. PLOS Pathogens 2016, 12: e1005852. PMID: 27658195, PMCID: PMC5033371, DOI: 10.1371/journal.ppat.1005852.Peer-Reviewed Original ResearchIL-17AMurine modelMetastatic leishmaniasisDisease chronicityHuman patientsInflammatory cytokines IL-17AIL-17A inhibitionPotent innate immunogenPresence of LRV1Cytokines IL-17AAbsence of IFNMetastatic complicationsImmunologic mechanismsStandard therapyCytokines IFNPrognostic valueOpen ulcerationDisease outcomeCutaneous leishmaniasisSecondary sitesSignificant associationLeishmania parasitesTherapeutic promiseLeishmaniasisLRV1Severe Cutaneous Leishmaniasis in a Human Immunodeficiency Virus Patient Coinfected with Leishmania braziliensis and Its Endosymbiotic Virus
Parmentier L, Cusini A, Müller N, Zangger H, Hartley M, Desponds C, Castiglioni P, Dubach P, Ronet C, Beverley S, Fasel N. Severe Cutaneous Leishmaniasis in a Human Immunodeficiency Virus Patient Coinfected with Leishmania braziliensis and Its Endosymbiotic Virus. American Journal Of Tropical Medicine And Hygiene 2016, 94: 840-843. PMID: 26834198, PMCID: PMC4824227, DOI: 10.4269/ajtmh.15-0803.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusLeishmania infectionCutaneous leishmaniasisPresence of LRV1Primary skin lesionsDrug treatment failureAggressive pathogenesisAntiretroviral therapyHIV patientsSpecies of LeishmaniaMurine leishmaniasisTreatment failureImmunodeficiency virusNasal lesionsRisk factorsEmergence of leishmaniasisSkin lesionsCutaneous afflictionsFurther exacerbationDisease severityLeishmania parasitesLeishmaniasisLeishmania braziliensisLRV1Patients
2013
The therapeutic potential of immune cross‐talk in leishmaniasis
Hartley M, Kohl K, Ronet C, Fasel N. The therapeutic potential of immune cross‐talk in leishmaniasis. Clinical Microbiology And Infection 2013, 19: 119-130. PMID: 23398405, DOI: 10.1111/1469-0691.12095.Peer-Reviewed Original ResearchConceptsMetastatic leishmaniasisCutaneous leishmaniasisLeishmania parasitesSelf-healing lesionsProtozoan parasitic diseaseEffective antileishmanial drugsSpecies of LeishmaniaDestructive lesionsImmune homeostasisCurrent treatmentTherapeutic strategiesImmune pathwaysNew drug targetsTherapeutic potentialParasitic diseasesAntileishmanial drugsLeishmaniasisLesionsPrevalent formDiseaseDrug targetsRNA virusesTreatmentVariable effectsParasites